This article is more than 5 years old. Information may no longer be current.
NYU Langone names liver tumor program director
Click Here to Manage Email Alerts
Theodore H. Welling, III, MD, has been named director of a new liver tumor program at NYU Langone’s Perlmutter Cancer Center.
Welling’s team will focus on refining the clinical treatment of primary liver cancer and hepatic metastases, translating laboratory breakthroughs into better treatments, and recruiting more investigators and clinicians.
“I am extremely excited to have the opportunity to lead such an innovative clinical and translational liver tumor program designed to advance therapies for hepatic malignancies,” Welling said in a press release. “The vision and leadership of NYU Langone and its Perlmutter Cancer Center has led to the creation of an excellent team of health care providers and researchers to help accomplish this mission.”
Welling’s work has focused on liver transplantation and laparoscopic liver surgery. He also has performed investigations into potential new treatments for cholangiocarcinoma and hepatocellular carcinoma, and he has conducted research into the role of the immune system and cancer stem cells in the development of liver cancer.
Welling previously served as co-director of the multidisciplinary liver tumor Program at University of Michigan Health System.
“Like many malignancies, symptoms of liver cancer do not appear in early stages, so it tends to be diagnosed when it is more advanced and less likely to be cured,” Benjamin G. Neel, MD, PhD, director of Perlmutter Cancer Center, said in the release. “Our goal is to help change the course of this disease, develop better ways to identify it early and improve patient outcomes. We are confident that, under Dr. Welling’s leadership, our liver cancer program can make major advances.”